Biotech RadarJobs updated

COMPANY

Vanda Pharmaceuticals

HQ: Washington, DC source · vandapharma.com ↗ · Mid-Atlantic

FDA-approved therapeutic company Clinical Phase 3

Keywords: oncology hematology hematologic malignancies Circadian Rhythm Sleep Disorders Schizophrenia Bipolar I Disorder Diabetic Gastroparesis Gastroparesis Motion Sickness Generalized Pustular Psoriasis Atopic Dermatitis Sleep Wake Disorders Chronobiology Disorders Idiopathic Gastroparesis Obesity Non 24 Hour Sleep Wake Disorder Autism Spectrum Disorder Major Depressive Disorder Moderate-to-severe Chronic Plaque Psoriasis Charcot Marie Tooth Disease Neuromuscular Diseases Ulcerative Colitis Social Anxiety Disorder Insomnia Disorder Nausea and Vomiting Relapsed or Refractory Hematologic Malignancies Hypertension Uncontrolled Hypertension Onychomycosis of Toenail Acneiform Eruptions Acne Vulgaris Hidradenitis Suppurativa Dry Eye Ichthyosis Palmoplantar Pustulosis Allergic Conjunctivitis Gene Mutations and Other Alterations Nec Treatment-resistant Pruritus Associated With Atopic Dermatitis Coronavirus Infection COVID-19 Sleep Disorder Neurological Disorder Sleep Disturbance

Location: Washington, DC · source · Oct 15, 2026

Profile checked Oct 10, 2026

82Trials (company is sponsor)2FDA records (2 yrs)

Timeline

  1. Trial start Phase 3: Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis source ↗
  2. Trial start Phase 3: A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use source ↗
  3. FDA FDA New drug/biologic (novel): BYSANTI (milsaperidone) — NDA220358, Feb 20, 2026. Applicant at approval: Vanda Pharmaceuticals, Inc. source ↗
  4. Trial start Phase 3: Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis source ↗
  5. FDA FDA New drug/biologic (novel): NEREUS (tradipitant) — NDA220152, Dec 30, 2025. Applicant at approval: Vanda Pharmaceuticals Inc. source ↗
  6. Partnership Partnership / licensing announced Oct 1, 2025. Source: SEC filing. source ↗
  7. Trial start Phase 2: An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye source ↗
  8. Trial start Phase 3: Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder source ↗
  9. Trial start Phase 2: Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension source ↗
  10. Trial start Phase 3: Randomized Withdrawal Study in Patients With Schizophrenia source ↗
  11. Trial start Phase 1/Phase 2: Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient source ↗
  12. Trial start Phase 2: Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis source ↗
  13. Trial start Phase 3: Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia source ↗
  14. Trial start Phase 3: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder source ↗
  15. Trial start Phase 2: A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use source ↗
  16. Trial start D: Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant source ↗
  17. Trial start Phase 1: Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions source ↗
  18. Trial start Phase 3: Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis source ↗
  19. Trial start Phase 3: Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness source ↗
  20. Trial start Phase 4: Safety and Tolerability of Open-Labeled Iloperidone in Adolescents source ↗
  21. Trial start Phase 3: Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness source ↗
  22. Trial start Phase 1: Food Effect Study of VHX-896 in Healthy Volunteers source ↗
  23. Trial start Phase 2: A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis source ↗
  24. Trial start Phase 1: Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers source ↗
  25. Trial start Phase 3: Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP source ↗

Showing 25 of 52 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) Showing 50 of 82

RecordTitlePhaseStatusStartPrimary completion
NCT04652882Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)DCompletedDec 9, 2020Sep 4, 2026 (actual)
NCT00254202Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaPhase 3CompletedNov 18, 2005Sep 26, 2006 (actual)
NCT05648591Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsPhase 4RecruitingMay 24, 2023Dec 31, 2028 (estimated)
NCT04028492Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisPhase 3CompletedAug 20, 2019Feb 21, 2025 (actual)
NCT06830044Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderPhase 3RecruitingMar 3, 20252028-03 (estimated)
NCT07362017Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisPhase 3RecruitingFeb 17, 20262028-08 (estimated)
NCT07223632Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual PatientPhase 1/Phase 2Active, not recruitingMay 13, 20252027-03 (estimated)
NCT07686081Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisPhase 3Recruiting2026-092029-04 (estimated)
NCT07221578Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderPhase 3Active, not recruitingSep 22, 20252026-12 (estimated)
NCT06953869Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaPhase 3RecruitingApr 21, 20252027-11 (estimated)
NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UsePhase 3RecruitingMar 27, 2026Dec 1, 2026 (estimated)
NCT06138613Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessPhase 3Active, not recruitingFeb 27, 2023Sep 30, 2027 (estimated)
NCT05366855Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPPhase 3TerminatedApr 21, 2022Jul 12, 2024 (actual)
NCT05352893Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPPhase 3CompletedApr 14, 2022Aug 17, 2023 (actual)
NCT03838926Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesPhase 1RecruitingSep 27, 20182027-12 (estimated)
NCT07090161Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionPhase 2RecruitingSep 15, 20252026-10 (estimated)
NCT07065773Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisPhase 2Active, not recruitingMay 5, 20252026-09 (estimated)
NCT06961968Randomized Withdrawal Study in Patients With SchizophreniaPhase 3RecruitingMay 14, 20252027-11 (estimated)
NCT06804603A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UsePhase 2CompletedFeb 25, 2025Oct 6, 2025 (actual)
NCT04697069A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform RashPhase 2TerminatedMay 4, 2021Dec 13, 2021 (actual)
NCT04856917A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisPhase 2CompletedMay 15, 2021Feb 1, 2022 (actual)
NCT04856930A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaPhase 2CompletedJul 7, 2021Jul 15, 2022 (actual)
NCT06494397Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsPhase 1CompletedJul 11, 2024Oct 24, 2024 (actual)
NCT07179055An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyePhase 2Recruiting2025-102026-09 (estimated)
NCT03619902A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular PsoriasisPhase 2CompletedJan 30, 2019Jan 20, 2021 (actual)
NCT04697056A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With IchthyosisPhase 2TerminatedJan 25, 2021Nov 19, 2021 (actual)
NCT03633396A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar PustulosisPhase 2CompletedMay 20, 2019Apr 23, 2021 (actual)
NCT04622345Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesPhase 2CompletedNov 21, 2020May 22, 2021 (actual)
NCT04474990Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With GastroparesisNot listedAvailableNot listedNot listed
NCT03772340Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessPhase 2CompletedDec 20, 2018Jun 6, 2019 (actual)
NCT05903924Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessPhase 3CompletedSep 9, 2023Apr 6, 2024 (actual)
NCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisPhase 3RecruitingJan 9, 20242025-12 (estimated)
NCT06803290Food Effect Study of VHX-896 in Healthy VolunteersPhase 1CompletedJun 21, 2022Dec 27, 2022 (actual)
NCT04327661Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessPhase 3CompletedNov 15, 2021Apr 1, 2023 (actual)
NCT06701396Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantDRecruitingOct 8, 2024Jun 30, 2025 (estimated)
NCT02970968Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisPhase 2Completed2016-112018-11 (actual)
NCT02651714Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisPhase 2CompletedJan 19, 2016Aug 4, 2017 (actual)
NCT02004041Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic DermatitisPhase 2CompletedDec 10, 2013Feb 19, 2015 (actual)
NCT04140695Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)Phase 3TerminatedOct 21, 2019Oct 14, 2020 (actual)
NCT03568331Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)Phase 3CompletedJul 9, 2018Dec 27, 2019 (actual)
NCT04819776Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderPhase 3CompletedMar 22, 2021Sep 7, 2022 (actual)
NCT04849559Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy VolunteersPhase 1/Phase 2CompletedFeb 1, 2021Sep 24, 2021 (actual)
NCT01218789Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionPhase 3Unknown status (ClinicalTrials.gov)Oct 28, 2010Dec 5, 2024 (estimated)
NCT04353401WGS Analysis of COVID-19 Positive PatientsNot listedCompletedAug 3, 2020Mar 9, 2022 (actual)
NCT05572281Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy VolunteersPhase 1CompletedMay 18, 2022Jun 15, 2022 (actual)
NCT06323655Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy SubjectsPhase 1CompletedJul 19, 2018Aug 28, 2018 (actual)
NCT05361707Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesPhase 3Unknown status (ClinicalTrials.gov)Jul 28, 20212025-07 (estimated)
NCT05344365A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease PsychosisPhase 2Withdrawn2022-062023-11 (estimated)
NCT02776215Study of the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsPhase 1CompletedOct 4, 2016Dec 20, 2017 (actual)
NCT04800237Evaluating the Effects of VQW-765 vs. Placebo in Performance AnxietyPhase 2CompletedFeb 23, 2021Aug 2, 2022 (actual)

FDA records (last 2 years)

Connect

See your connections at Vanda Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback